ensysce.com
Open in
urlscan Pro
141.193.213.20
Public Scan
Submitted URL: http://ensysce.com/
Effective URL: https://ensysce.com/
Submission: On December 15 via api from US — Scanned from DE
Effective URL: https://ensysce.com/
Submission: On December 15 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
Skip to content Main Logo Menu * About Us * Our Philosophy * The Industry and Us * Our Strategy * Our Technology * Key Applications * Clinical Programs * Preclinical Programs * Pipeline * Our Partnerships * Our Team * Executive Management * Board of Directors * Clinical Advisory Board * Contact Us * Investors HOME Our Technology INNOVATIVE CHEMISTRY TRANSFORMATIVE THERAPIES Find out more About us WHAT WE DO We’re a biotech company committed to stemming the prescription drug abuse epidemic. About Us Our Strategy DELIVERING INNOVATIVE TECHNOLOGY * TAAP™ PREVENTING DRUG ABUSE A highly novel platform that reduces the possibility of abuse by snorting, extracting, injection or chewing. * UNIVERSAL APPLICATION Our technology can be applied to a large complement of oral prescription drugs * MPAR™ PREVENTING DRUG OVERDOSE Our unique Multi-Pill Abuse Resistant technology MPAR™ provides another layer of protection, reducing the possibility of overdose. Investment LONG TERM OPPORTUNITY Events & Presentations 2022 Annual Meeting of Stockholders Find Out More Events & Presentations Special Meeting of Stockholders Find Out More Events & Presentations Ensysce Corporate Overview Find Out More Events & Presentations 2022 Annual Meeting of Stockholders Find Out More Events & Presentations Special Meeting of Stockholders Find Out More Dr. Vince Clinical Research Announces Dosing of Ensysce’s PF614 Compound in Human Abuse Read More Ensysce Biosciences releases updated investor presentation ahead of corporate update call. Read More Ensysce Biosciences provides business update and reports second quarter 2022 financial results. Read More Ensysce Biosciences announces completion of $8 million convertible note financing. Read More Ensysce Biosciences announces positive Bioequivalence (BE) study data of novel “TAAP” opioid PF614 and provides timing of corporate update call Read More Dr. Vince Clinical Research Announces Dosing of Ensysce’s PF614 Compound in Human Abuse Read More Ensysce Biosciences releases updated investor presentation ahead of corporate update call. Read More Our Team BRILLIANT MINDS AND VISION View our Team We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization. D. LYNN KIRKPATRICK, PHD Chief Executive Officer Close modal D. LYNN KIRKPATRICK PHD CHIEF EXECUTIVE OFFICER > “Our technology advancements can change people’s lives. We are striving to > make a difference.” * Background in medicinal chemistry and pharmacology, drug discovery and development * Co-founded 2 start up companies * Developed three targeted small molecule oncology drugs from discovery to clinic * Experience in private and public company raising funds from private, public and government sources RICHARD WRIGHT, MSE, MBA Chief Business Officer Close modal RICHARD WRIGHT MSE, MBA CHIEF BUSINESS OFFICER > “As crisis and consolidation occur in the opioid sector, Ensysce is positioned > to become both best in class and market leader in abuse deterrence” * Background in Intellectual Property monetization, banking, venture capital * Co-founder of an immunology biotech company, later sold to private equity DAVE HUMPHREY Chief Financial Officer Close modal DAVE HUMPHREY CHIEF FINANCIAL OFFICER > “We know our approaches cannot only provide advances in pain medicine but they > also benefit our society. Our team is inspired by this combined mission.” * Extensive experience in entrepreneurial environments * Multiple equity and debt financing, including IPOs * Focused on financial infrastructure, internal controls with merger and acquisition strategies BILL SCHMIDT Chief Medical Officer. Close modal BILL SCHMIDT CHIEF MEDICAL OFFICER. > “Being able to protect against opioid overdose — using MPAR technology — will > set Ensysce apart from all other conventional and abuse-deterrent opioid > products.” JEFFREY MILLARD, PHD Chief Operating Officer Close modal JEFFREY MILLARD PHD CHIEF OPERATING OFFICER > “Our unique prodrugs provide intrinsic safety and efficacy, obviating the need > for confounding formulation tricks as abuse deterrents” * Industrial experience in CMC (chemistry, manufacturing, and controls) * 7 IND submissions (CDER, CBER, and IMPDs); directed CMC efforts from discovery, in-licensing to commercial launch * PhD in Pharmaceutical Sciences from University of Arizona GEOFF BIRKETT Chief Commercial Officer Close modal GEOFF BIRKETT CHIEF COMMERCIAL OFFICER > “We target the toughest diseases where suffering is high and abuse or overdose > can be an issue. Our mission is simple, reduce suffering using advanced > technologies” * Held leadership roles in major Pharma. companies in UK/ Germany/ USA and Global. * Developed several major central nervous system drugs from phase 2 to launch. * Launched 5 major market leaders including Prozac, Seroquel, Zomig and Nicorette. * Extensive biotechnology leadership experience in pain space. LINDA PESTANO Chief Development Officer Close modal LINDA PESTANO CHIEF DEVELOPMENT OFFICER > “We can’t stop severe and chronic pain, but the Ensysce team are committed to > helping manage it safely, using advanced chemistry” * Experienced in the design of pre-clinical programs focused on building IND-enabling data packages for lead candidate compounds intended for the treatment or diagnosis of cancer and inflammatory diseases * PhD in Immunology from Tufts, Postdoctoral Research at Dana Farber, Harvard Medical School Main Logo BIOTECH COMPANY COMMITTED TO STEMMING THE PRESCRIPTION DRUG ABUSE EPIDEMIC. Our proprietary prodrug technologies are designed to improve the care of patients with severe pain while reducing the human and economic costs associated with prescription drug abuse. ABOUT US * Our philosophy * The Industry and Us OUR STRATEGY * Our Technology * Key Applications * Clinical Programs * Preclinical Programs * Pipeline * Our Partnerships OUR TEAM * Executive Management * Board of Directors * Clinical Advisory Board CONTACT US INVESTORS FOLLOW ENSYSCE ON SOCIAL MEDIA: * /company/Ensyscebio * @Ensyscebio * /Ensyscebio